Targets › PNLIP
1 program from 1 company in 1 trial: 1 Phase 2; Metabolic and endocrine; next expected readout Aug 2027.
Plays an important role in fat metabolism. It preferentially splits the esters of long-chain fatty acids at positions 1 and 3, producing mainly 2-monoacylglycerol and free fatty acids, and shows considerably higher activity against insoluble emulsified substrates than against soluble ones. (UniProt, P16233)
Open in Phaseline: the race on PNLIP, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Texas Southwestern Medical Center | Orlistat Gastric lipase inhibitor; Pancreatic lipase inhibitor | LIPF, PNLIP | Phase 2 | Type 1 Hyperlipoprotenemia | Aug 2027 |
Type 1 Hyperlipoprotenemia (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.